Psychedelic treatment of functional neurological disorder: a systematic review.
LSD
conversion disorder
functional neurological disorder
psilocybin
psychedelics
Journal
Therapeutic advances in psychopharmacology
ISSN: 2045-1253
Titre abrégé: Ther Adv Psychopharmacol
Pays: England
ID NLM: 101555693
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
09
2019
accepted:
11
02
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
22
5
2020
Statut:
epublish
Résumé
Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatric services, yet the therapeutic evidence base is somewhat limited. There has been recent interest in the therapeutic potential of psychedelics such as psilocybin and lysergic acid diethylamide (LSD), and in recent studies psychedelics have shown promise in treating a range of neuropsychiatric conditions. Modification of neural circuits associated with self-representation is thought to underlie some of this effect, and as some contemporary theories of FND focus on aberrant somatic self-representation, psychedelics may therefore represent an unexplored treatment option for FND. We systematically reviewed studies involving the use of psychedelics in FND. Nine studies published between 1954 and 1967, with a total of 26 patients, were identified. Due to restriction of licencing of psychedelic drugs since this period, no modern studies were identified. In most cases, patients received a course of psychotherapy with variable adjunctive administration of psychedelics (in a combination known as 'psycholytic therapy'), with protocols varying between studies. Of those treated, 69% (
Identifiants
pubmed: 32435447
doi: 10.1177/2045125320912125
pii: 10.1177_2045125320912125
pmc: PMC7225815
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2045125320912125Subventions
Organisme : Department of Health
ID : CS-2017-17-007
Pays : United Kingdom
Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: King’s College London receives grant funding for phase I and II trials with psilocybin, led by JR and AY, from Compass Pathways Ltd. JR has attended trial related meetings paid for by Compass Pathways Ltd. Compass Pathways Ltd. had no influence over the inception, design, execution or publication of this work.
Références
J Psychopharmacol. 2014 Nov;28(11):983-92
pubmed: 25213996
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):239-47
pubmed: 22056967
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
J Ment Sci. 1954 Apr;100(419):491-507
pubmed: 13175011
BMJ Evid Based Med. 2018 Apr;23(2):60-63
pubmed: 29420178
Philos Ethics Humanit Med. 2012 Jan 13;7:2
pubmed: 22243976
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
J Psychopharmacol. 2008 Aug;22(6):603-20
pubmed: 18593734
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):961-6
pubmed: 21325661
J Ment Sci. 1957 Apr;103(431):332-43
pubmed: 13429304
J Psychopharmacol. 2015 Mar;29(3):270-9
pubmed: 25744618
Handb Clin Neurol. 2017;139:47-60
pubmed: 27719864
Neuropsychologia. 2010 May;48(6):1782-8
pubmed: 20206641
J Clin Neurosci. 2016 Jun;28:93-6
pubmed: 26754851
J Rehabil Med. 2014 Feb;46(2):181-7
pubmed: 24248149
Clin EEG Neurosci. 2015 Jan;46(1):4-15
pubmed: 25432161
Sem Hop. 1961 Nov 8;37:3061-2
pubmed: 13888139
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4853-8
pubmed: 27071089
Br J Psychiatry. 2005 Jun;186:457-8
pubmed: 15928353
Neurology. 2010 Jun 15;74(24):1986-94
pubmed: 20548043
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
Am J Psychiatry. 2004 Dec;161(12):2271-6
pubmed: 15569899
Int J Neuropsychopharmacol. 2017 May 1;20(5):422-427
pubmed: 28177082
Neurosci Biobehav Rev. 2017 Mar;74(Pt A):185-203
pubmed: 28108416
Arch Psicol Neurol Psichiatr. 1959 Mar-Jun;20:171-91
pubmed: 13827933
J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):220-6
pubmed: 24029543
Cortex. 2008 May;44(5):494-506
pubmed: 18387583
Med J Aust. 1964 Jan 4;1:5-8
pubmed: 14116718
JAMA Neurol. 2018 Sep 1;75(9):1132-1141
pubmed: 29868890
J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):704-711
pubmed: 30455406
Am J Psychiatry. 1963 Oct;120:396-7
pubmed: 14069470
Med J Aust. 1964 Jan 11;1:36-41
pubmed: 14105435
J Psychopharmacol. 2015 Mar;29(3):280-8
pubmed: 25586402
Clin Psychol Rev. 2016 Jul;47:55-70
pubmed: 27340856
J Nerv Ment Dis. 1958 Dec;127(6):528-39
pubmed: 13621221
Addict Behav Rep. 2019 Dec;10:
pubmed: 31799366
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
BMJ. 2005 Oct 29;331(7523):989
pubmed: 16223792
Neurosci Lett. 2011 Apr 15;493(3):76-9
pubmed: 21276828
J Psychopharmacol. 2012 Jul;26(7):994-1002
pubmed: 22406913
Lancet. 2010 Nov 6;376(9752):1558-65
pubmed: 21036393
Brain. 2010 May;133(Pt 5):1526-36
pubmed: 20371508
PLoS One. 2013 Aug 19;8(8):e63972
pubmed: 23976938
J Clin Psychiatry. 2006 Nov;67(11):1735-40
pubmed: 17196053
Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60
pubmed: 27441452
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
J Neurol. 2014 Dec;261(12):2370-7
pubmed: 25239392
BMC Neurol. 2019 Oct 21;19(1):242
pubmed: 31638942
Addiction. 2004 Jun;99(6):686-96
pubmed: 15139867
BMC Psychiatry. 2016 Jun 10;16:195
pubmed: 27283002
J Psychopharmacol. 2016 Dec;30(12):1220-1229
pubmed: 27856684
Clin Neurol Neurosurg. 2010 Nov;112(9):747-51
pubmed: 20646830
Neuropsychologia. 2007 May 15;45(9):2051-8
pubmed: 17367826
Arch Gen Psychiatry. 2011 Jan;68(1):71-8
pubmed: 20819978
J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):484-490
pubmed: 27694498
JAMA Psychiatry. 2014 Sep;71(9):997-1005
pubmed: 24989152
J Psychosom Res. 2010 Sep;69(3):241-8
pubmed: 20708446
Neuropharmacology. 2018 Nov;142:200-218
pubmed: 29284138
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):810-3
pubmed: 21257981
Braz J Psychiatry. 2015 Jan-Mar;37(1):13-20
pubmed: 25806551
Front Neurosci. 2010 Aug 13;4:
pubmed: 20802802
Ann N Y Acad Sci. 2008 Mar;1124:1-38
pubmed: 18400922
Eur J Neurol. 2015 May;22(5):866-73
pubmed: 25708187
Proc R Soc Med. 1960 Nov;53:927-9
pubmed: 13762422
Epilepsia. 2014 Jan;55(1):156-66
pubmed: 24446955
J Affect Disord. 2008 Feb;106(1-2):1-27
pubmed: 17707915
Neuroimage. 2009 Sep;47(3):1026-37
pubmed: 19450695
Brain. 2012 Nov;135(Pt 11):3495-512
pubmed: 22641838
J Nerv Ment Dis. 1973 Dec;157(6):410-9
pubmed: 4148471